Table 1 Cytotoxicity of the target compounds 5a–u indicated with their IC₅₀ values in different human cancer cells

5a

0.7 ± 0.1

3.6 ± 1.7

1.3 ± 0.3

5b

4.9 ± 1.3

6.5 ± 1.2

5.8 ± 0.8

5c

21.4 ± 1.2

21.1 ± 4.1

35.2 ± 2.6

5d

14.4 ± 1.8

23.6 ± 1.4

24.5 ± 0.4

5e

11.6 ± 1.3

14.5 ± 2.9

20.1 ± 1.3

5f

8.6 ± 1.0

11.6 ± 1.5

14.7 ± 1.6

5g

9.7 ± 0.3

NI

NI

5h

4.9 ± 0.8

8.7 ± 0.6

10.4 ± 0.5

5i

15.7 ± 0.3

18.9 ± 0.4

22.1 ± 1.6

5j

16.4 ± 2.1

24.9 ± 2.9

27.3 ± 3.4

5k

NI

NI

NI

5l

17.8 ± 2.2

14.0 ± 0.2

15.4 ± 2.0

5m

12.1 ± 0.5

18.1 ± 1.3

25.3 ± 0.5

5n

14.6 ± 3.2

19.2 ± 0.5

25.5 ± 3.1

5o

NI

34.2 ± 5.0

30.4 ± 3.6

5p

17.1 ± 4.5

28.4 ± 1.7

19.2 ± 2.2

5q

13.0 ± 2.1

31.7 ± 1.1

20.6 ± 1.2

5r

4.1 ± 0.8

5.9 ± 1.2

5.9 ± 1.4

5s

16.3 ± 0.2

15.4 ± 3.2

12.9 ± 0.7

5t

4.7 ± 0.9

7.5 ± 1.7

11.6 ± 2.0

5u

8.3 ± 0.8

11.4 ± 0.2

8.0 ± 1.0

DOXO

0.22 ± 0.02

0.14 ± 0.05

0.23 ± 0.02

5-FU

21.0 ± 0.75

14.1 ± 0.26

18.4 ± 1.1

Sorafenib

6.5 ± 0.5

14.6 ± 0.2

11.0 ± 0.6